AVNS

Avanos Medical, Inc.

Fundamental data last updated:October 28, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

Not Scheduled

Business Summary

Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.

 


Analyze AVNS on TradingView

VALUATION

P/E

-16.65

Market Cap ($M USD)

$1.17B

Forward P/E

24.99

PEG

-1.50

PRICE TO SALES

1.64

PRICE TO BOOK

1.48

EV / EBITDA

-57.57

5-Year Average P/E

Free Cash Flow Yield

0.64%

DCF Value

$-16.82

Graham Number

N/A

Price to FCF

156.10

EV to FCF

165.80

Earnings Yield

-5.99%

FCF Yield

0.64%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.50

Next Year EPS Growth Estimate

$1.00

Next Year Revenue Growth Estimate

$710.00M

Return on Equity (ROE)

-8.91%

FREE CASH FLOW

Operating Margin

-7.92%

Debt-to-Equity

0.18

Piotroski F-Score

4

Altman Z-Score

2.30

Return on Invested Capital (ROIC)

-6.03%

Current Ratio

2.48

Quick Ratio

1.40

Net Debt to EBITDA

-3.37

Interest Coverage

-7.88

Gross Profit margin

48.55%

FCF PER SHARE

$0.16

REVENUE PER SHARE

$15.43

Analyze AVNS on TradingView

Gainseekers Quantitative Analysis

Summary

Avanos Medical, Inc. is a perplexing case of valuation misalignment. Despite a snapshot price that has traded above its DCF value, the Forward P/E of 19.84 suggests some optimism for future earnings recovery. However, the negative Earnings Yield and a concerning Altman Z-score of 2.29 indicate potential financial distress. The market seems to be pricing in a turnaround, yet the negative ROIC and operating margins cast doubt on management’s ability to deliver. The absence of a Graham Number further complicates the valuation narrative, leaving investors questioning the true intrinsic value.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, Avanos is well-positioned to leverage AI advancements in healthcare. The sector's inherent need for innovation aligns with AI-driven improvements in diagnostics and patient care. However, the company's current financial metrics suggest it may struggle to capitalize on these opportunities without significant strategic shifts.

The Bull Case

For the discerning GARP investor, Avanos presents a curious opportunity. The company's low Debt/Equity ratio of 0.17 and a reasonable Piotroski F-Score of 4 suggest some financial discipline. Despite a meager FCF Yield, the robust Current Ratio of 2.48 indicates liquidity strength. These factors, combined with a substantial Gross Profit Margin of 48.55%, hint at underlying pricing power and operational efficiency that could be unlocked with the right strategic maneuvers.

The Bear Case

Yet, the bear case looms large. Avanos's negative EPS and a staggering EV to EBITDA ratio of -66.71 highlight severe profitability issues. The stock's proximity to its 52-week high, just 0.04% away, suggests technical overextension. With a Price to FCF of 154.83, the valuation appears stretched, especially given the lack of dividend yield and negative operating margins. These metrics paint a picture of a company struggling to convert sales into sustainable cash flow.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$23.00

Institutional Ownership %

1-Year Beta

1.57

Insider Buying % (6 Mo)

Distance to 52-Week High

2.00%

Distance to 52-Week Low

62.77%

EARNINGS SURPRISE %

37.50%

50-DAY SMA

$24.90

200-DAY SMA

$16.92

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.